Product Suite &
Pharmaceutical Pipeline
Product Suite
Market-ready assets include management tools for advanced wound care and dermatitis. Pipeline assets include FleX™ Antimicrobial, an antimicrobial regenerative collagen powder, as well as Xeal® Silicone, a non-adherent, antimicrobial silicone dressing.
Hexagen® Antimicrobial
FDA Cleared
Xeal® Antimicrobial Wound Dressing
FDA Cleared
AtopX™ Eczema Management Tool
FDA Cleared
FleX™ Antimicrobial Collagen Matrix
510k Submitted
Xeal® Non-Stick Antimicrobial Gauze
In Development
X-Fill™ Hemostat
In Development
Pharmaceutical Pipeline
We are engaged in the pursuit of drug therapies for the treatment of onychomycosis, herpes zoster opthalmicus, and COVID-19.
*Lead candidate
**Orphan candidate
***CDC Emerging Threat
Bacterial Skin Infection*
Completed Pre-IND Meeting and CMC
Onychomycosis*
Completed Pre-IND Meeting and CMC
Intranasal COVID-19
Completed Phase 2B-OUS Approval in Process
Eczema
Phase 2B Ready
Herpes Zoster Ophthalmicus (HZO)**
Completed Animal Model
Basal Cell Carcinoma
Completed Animal Model
Intranasal Candida Auris***
Completed Animal Model
